NG-641 clinical trials
Also written NG-641.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses NG-641 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- NG-641
- 2
Studies by the year they started
3 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Akamis Bio (3)
Studies
Open first, then newest update. How each study uses NG-641 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckCompletedPhase 1Akamis BioNCT04830592Written as NG-641How we know
- Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursCompletedPhase 1Akamis BioNCT05043714Written as NG-641 in combination with NivolumabHow we know
- First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral VectorCompletedPhase 1Akamis BioNCT04053283Written as NG-641How we know
Codes
What other systems call NG-641 · ClinicalTrials.gg INT017154
- UNII (FDA) L93WSG9AAUNG-641One source FDA
- NCI Thesaurus C168790Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | L93WSG9AAU | NG-641 | One source FDA |
| NCI Thesaurus | C168790 | Enadenotucirev-expressing FAP/CD3 Bispecific FAP-TAc NG-641 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.